Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colloid vs Crystalloid Volume Resuscitation and Intensive vs Conventional Insulin Therapy in Severe Sepsis and Septic Shock
NCT00135473Phase 3Completed
- Sponsor
- SepNet
- Start
- Apr 2003
- Modality
- Polymer-based Nanoparticles, Lipid-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of hetastarch and human insulin in sepsis and septic shock (4 arms), sponsored by SepNet. Primary endpoints: Mortality at 28 days and Mean Sepsis-related Organ Failure Assessment Score. Started Apr 2003; status: completed.
02
Drugs
hetastarchhuman insulin
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT00135473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135473.